Actively Recruiting
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Led by FengYan Jin · Updated on 2026-04-03
50
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
F
FengYan Jin
Lead Sponsor
A
Affiliated Hospital of Hebei University
Collaborating Sponsor
AI-Summary
What this Trial Is About
At present, there is no prospective study on the treatment of first-relapsed multiple myeloma with daratumumab plus pomalidomide and dexamethasone (Dara-Pd). A prospective, multicenter, open, non-interventional, observational clinical study to evaluate the efficacy and safety of Dara-Pd in patients with first relapse multiple myeloma.
CONDITIONS
Official Title
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be 18 years or older, any gender
- Diagnosed with symptomatic multiple myeloma based on 2014 IMWG criteria with measurable disease
- Experiencing first relapse of multiple myeloma
- Receiving first-line anti-multiple myeloma therapy
- First-line therapy must include proteasome inhibitors and immunomodulators (RVD)
- Achieved at least partial response to one prior regimen
- Signed informed consent form
- Women of childbearing potential must use two reliable birth control methods starting 4 weeks before dosing and continuing 3 months after last dose, and have a negative pregnancy test within 14 days before randomization
You will not qualify if you...
- Diagnosis of inactive multiple myeloma, primary amyloidosis, MGUS, or smoldering myeloma
- Relapsed and refractory myeloma defined as nonresponsive disease on salvage therapy or progression within 60 days after last therapy following minimal response or better
- Primary refractory myeloma defined as nonresponsive disease without ever achieving minimal response to therapy
- Previous treatment with daratumumab or pomalidomide
- History of other malignancies within 3 years before randomization unless considered cured with minimal risk of recurrence
- Uncontrollable psychiatric disorders
- Unable or suspected unable to comply with study protocol
- Any condition that may prevent or confound study assessments or is not in participant's best interest
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Hospital of Jilin University
Changchun, Jilin, China, 130000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here